• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by NuCana plc

    3/19/26 5:23:17 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCNA alert in real time by email
    S-8 1 d19997ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 19, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    NUCANA PLC

    (Exact name of registrant as specified in its charter)

     

     

     

    England and Wales   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

    3 Lochside Way

    Edinburgh EH12 9DT

    Tel: +44 (0)131 357 1111

      Not Applicable
    (Address of principal executive offices)   (Zip code)

    NuCana BioMed Limited 2016 Share Option Scheme (Including Enterprise Management Incentives &

    Incentive Stock Options), as amended

    NuCana plc 2020 Long-Term Incentive Plan, as amended

    (Full title of the plan)

    Corporation Service Company

    251 Little Falls Drive Wilmington, DE 19808

    United States

    (Name and address of agent for service)

    +1 302 636 5400

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    William C. Hicks, Esq.

    John T. Rudy, Esq.

    Allyson Wilkinson, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    One Financial Center

    Boston, MA 02111

    Telephone: +1 617 542 6000

    Facsimile: +1 617 542 2241

     

    Hugh S. Griffith

    Chief Executive Officer

    NuCana plc

    3 Lochside Way

    Edinburgh, EH12 9DT

    United Kingdom

    Telephone: +44 (0)131 357 1111

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☐
         Emerging Growth Company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement registers an aggregate of 20,000,000,000 additional ordinary shares, nominal value £0.0004 per share (“Ordinary Shares”) which are represented by American Depositary Shares (“ADSs”), each of which represents five thousand Ordinary Shares, of NuCana plc (the “Registrant”) reserved under the NuCana BioMed Limited 2016 Share Option Scheme (Including Enterprise Management Incentives & Incentive Stock Options), as amended (the “2016 Share Option Scheme”) and the NuCana plc 2020 Long-Term Incentive Plan, as amended (the “2020 Plan”), representing (i) 3,478,076,733 Ordinary Shares issuable upon the exercise of options granted to officers, directors, employees and consultants on June 20, 2025, (ii) 3,851,136,696 Ordinary Shares issuable upon the exercise of options granted to officers, directors, employees and consultants on January 14, 2026, and (iii) an increase of 12,670,786,571 Ordinary Shares that may become issuable under the 2020 Plan pursuant to the terms of the 2020 Plan.

    This Registration Statement registers additional securities of the same class as other securities for which registration statements filed on Form S-8 (File No.  333-223476 and File No. 333-248135) relating to employee benefit plans are effective. The information contained in the Registrant’s registration statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on March  7, 2018 (File No. 333-223476) and August  19, 2020 (File No. 333-248135), to the extent relating to the registration of Ordinary Shares issuable under the 2016 Share Option Scheme and the 2020 Plan, are hereby incorporated by reference pursuant to General Instruction E of Form S-8.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents, which have been filed with the Commission by NuCana plc (the “Registrant”), pursuant to the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as applicable, are hereby incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

     

      (a)

    the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Commission on March 19, 2026;

     

      (b)

    the Registrant’s Reports on Form 6-K furnished to the Commission on January 6, 2026 and March 19, 2026; and

     

      (c)

    the description of the Registrant’s Ordinary Shares which are represented by the Registrant’s ADSs, each of which represents five thousand Ordinary Shares, contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on September 22, 2017, including any amendments or reports filed for the purpose of updating such description.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

    Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement, except as to specific sections of such statements as set forth therein.

    Under no circumstances shall any information furnished on Form 6-K be deemed incorporated herein by reference unless such Form 6-K expressly provides to the contrary.


    Item 8. Exhibits.

     

    Exhibit

    Number

      

    Exhibit Description

       Filed
    Herewith
         Incorporated
    by Reference
    herein from
    Form or
    Schedule
        Filing Date      SEC File/
    Reg. Number
     
      3.1    Articles of Association of the Registrant.        

    F-1/A

    (Exhibit 3.1)


     

        5/2/2025        333-286716  
      4.1    Form of Certificate Evidencing Ordinary Shares.        

    F-1/A

    (Exhibit 4.1)

     

     

        9/18/2017        333-220321  
      4.2    Amended and Restated Deposit Agreement, by and among the Registrant, Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of ADSs issued thereunder.        

    F-3/A

    (Exhibit 4.2)

     

     

        6/18/2025        333-281576  
      4.3    Amendment No.  1 to Amended and Restated Deposit Agreement, by and among the Registrant, the Depositary, and all Holders and Beneficial Owners of ADSs issued thereunder.        

    20-F

    (Exhibit 2.2)

     

     

        3/19/2026        001-38215  
      4.4    Form of American Depository Receipt (included in Exhibit 4.3).        

    20-F

    (Exhibit 2.2)

     

     

        3/19/2026        001-38215  
      4.5    Form of Pre-Funded Warrant.        

    F-1/A

    (Exhibit 4.6)

     

     

        5/2/2025        333-286716  
      5.1    Opinion of Bristows LLP.      X          
     10.1+    NuCana BioMed Limited 2016 Share Option Scheme (Including Enterprise Management Incentives  & Incentive Stock Options), as amended, and form of option agreements thereunder.        

    20-F

    (Exhibit 4.4)

     

     

        3/19/2026        001-38215  
     10.2+    NuCana plc 2020 Long-Term Incentive Plan, as amended, and form of option agreement thereunder.        

    20-F

    (Exhibit 4.5)

     

     

        3/19/2026        001-38215  
     23.1    Consent of Ernst & Young LLP, independent registered public accounting firm.      X          
     23.2    Consent of Bristows LLP (included in the opinion filed as Exhibit 5.1).      X          
     24.1    Powers of Attorney (included on the signature page of this Registration Statement).      X          
    107    Filing Fee Table.      X          
     
    + 

    Indicates management contract or compensatory plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Edinburgh, United Kingdom, on March 19, 2026.

     

    NUCANA PLC
    By:   /s/ Hugh S. Griffith
      Name: Hugh S. Griffith
      Title: Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Hugh S. Griffith and Ian Webster, and each of them, as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him and in his name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Hugh S. Griffith

    Hugh S. Griffith

      

    Chief Executive Officer

    (Principal Executive Officer)

      March 19, 2026

    /s/ Ian Webster

    Ian Webster

      

    Interim Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

      March 19, 2026

    /s/ Andrew Kay

    Andrew Kay

       Director and Chairman  

    March 19, 2026

    /s/ Cyrille Leperlier

    Cyrille Leperlier

       Director   March 19, 2026

    /s/ Martin Mellish

    Martin Mellish

       Director   March 19, 2026

    /s/ Elliott Levy

    Elliott Levy

       Director   March 19, 2026


    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT

    Pursuant to the Securities Act, the undersigned, the duly authorized representative in the United States of NuCana plc, has signed this registration statement or amendment thereto in Spring Branch, Texas on March 19, 2026.

     

    Authorized U.S. Representative
    NUCANA, INC.
    By:   /s/ Jeffrey Bloss, M.D.
      Name: Jeffrey Bloss, M.D.
      Title:  Chief Medical Officer
    Get the next $NCNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NCNA

    DatePrice TargetRatingAnalyst
    8/30/2024Outperform → Mkt Perform
    William Blair
    3/3/2022Outperform → Market Perform
    Cowen & Co.
    11/24/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NCNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NuCana downgraded by William Blair

    William Blair downgraded NuCana from Outperform to Mkt Perform

    8/30/24 7:44:58 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana downgraded by Cowen & Co.

    Cowen & Co. downgraded NuCana from Outperform to Market Perform

    3/3/22 6:12:40 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on NuCana with a new price target

    HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously

    11/24/21 6:13:12 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

    NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, March 19, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") today announced financial results for the fourth quarter and year ended December 31, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We are excited to enter 2026 with significant momentum as we continue to advance the development of our P

    3/19/26 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

    Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued Listing Criteria Well Capitalized with Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced financial results for the third quarter ended September 30, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We recently announced promising data for both NUC-7738 and NUC-3373 that continue to support the potential of our ProTides to deliver

    11/13/25 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Bloss Jeffrey D.

    3 - NuCana plc (0001709626) (Issuer)

    3/19/26 5:52:36 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Kay Andrew Martin

    3 - NuCana plc (0001709626) (Issuer)

    3/18/26 5:36:55 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Webster Ian Alexander

    3 - NuCana plc (0001709626) (Issuer)

    3/18/26 5:39:28 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    SEC Filings

    View All

    SEC Form S-8 filed by NuCana plc

    S-8 - NuCana plc (0001709626) (Filer)

    3/19/26 5:23:17 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by NuCana plc

    20-F - NuCana plc (0001709626) (Filer)

    3/19/26 4:23:30 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    3/19/26 4:07:35 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Leadership Updates

    Live Leadership Updates

    View All

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

    EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized

    11/1/21 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

    EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and

    8/10/21 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NuCana plc

    SC 13G/A - NuCana plc (0001709626) (Subject)

    10/4/24 10:14:46 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by NuCana plc (Amendment)

    SC 13D/A - NuCana plc (0001709626) (Subject)

    2/27/24 4:29:36 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NuCana plc (Amendment)

    SC 13G/A - NuCana plc (0001709626) (Subject)

    2/14/24 4:26:01 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care